65 results about "Fixed dose" patented technology

An embodiment relates to an active implantable medical device (AIMD) comprising: a permeability module to allow ingress of a fluid into an osmotic agent chamber of the AIMD, a compressible piston, a drug chamber comprising a drug or being provided to receive a drug and a valve module to allow flow of the drug from the drug chamber to outside the AIMD through one or more drug outlets present in the AIMD, wherein the AIMD has dimensions that allow the AIMD to be implanted, subcutaneously, in a human body.

An embodiment relates to an active implantable medical device (AIMD) comprising: a permeability module to allow ingress of a fluid into an osmotic agent chamber of the AIMD, a compressible piston, a drug chamber comprising a drug or being provided to receive a drug and a valve module to allow flow of the drug from the drug chamber to outside the AIMD through one or more drug outlets present in the AIMD, wherein the AIMD has dimensions that allow the AIMD to be implanted, subcutaneously, in a human body.

The invention includes dry powder nintedanib formulation for dispersion and inhalation administration including salts thereof, indolinone derivative or salts thereof and in fixed dose combinations with carrier agents and other active ingredients. The aerosol delivery combination formulation may be administered as an inhaled aerosol over a few actuations or by two or more actuations. Each dose may be administered one or more times daily on a regular or interval daily dosing regimen. The special formulation parameters of the invention include the selection of the salt for complexation with the form of nintedanib used for an isolated dry powder along with particle size distributions and combination with a force control agent for improved aerosol delivery. Methods of the invention include therapeutically effective doses of the described invention used to treat interstitial lung disease.

The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) Netupitant or salt or hydrate thereof, and (b) Palonosetron or salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, the method comprising: (i) wet granulating a dry mixture comprising Netupitant or a salt or hydrate thereof, filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising Palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules, (ii) blending the granules with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compressing of the lubricated granules to produce a tablet. The invention further relates to the pharmaceutical composition for use in the treatment and / or prevention of nausea and / or vomiting, preferably in the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetogenic cancer chemotherapy, for example cisplatin cancer chemotherapy.

The invention relates to the technical field of environmental toxicology, in particular to a construction method and application of micro-nano plastic combined toxicity (AOP) based on multi-omics integration, and the construction method comprises the following steps: respectively carrying out single exposure culture of multi-target risk substances by adopting human-derived hepatocyte HepaRG cells; determining a combined exposure dose; cell treatment and sample preparation; transcriptome analysis; analyzing metabolome; transcriptome and metabolome data are integrated, pathway cross analysis is carried out, a gene-metabolite interaction network is constructed, and a core regulation and control module is identified; and constructing an AOP framework: determining a molecular initial event, a key event and a harmful outcome of the AOP framework based on the integrated data, and importing an AOP-WIKI platform to generate a standardized AOP framework. According to the method, the limitation of a traditional single omics and fixed dose model is broken through, full-chain dynamic association from a molecular initial event to a harmful outcome is realized, and a scientific basis is provided for combined pollution risk assessment in the fields of environment and food.

The invention relates to a multiuse fixed dose injection device for ejecting multiple pre-defined fixed doses of a liquid drug. The injection device comprises a housing structure, a dose selection button and a piston rod assembly. The housing structure is configured for holding a loaded cartridge containing the liquid drug. The dose selection button is functionally coupled to the housing structure for selecting one of the pre-defined fixed dose and the piston rod assembly is distally adapted to move a piston inside the loaded cartridge and adapted to carry a gear wheel, which is rotatably coupled with a piston rod. The injection device further comprises a first toothed rack associated with the housing structure and a second toothed rack associated with the dose button. The gear wheel and the first toothed rack are permanently engaged both during dose selection and during dose ejection, and the gear wheel and the second toothed rack are disengaged during dose selection and engaged during dose ejection.

The utility model discloses a fixed dose injector, which relates to the technical field of injectors, and comprises a needle cylinder, the core rod is arranged on the inner side of the needle cylinder in a sliding mode, and the core rod is integrally formed by two or more than two core rod grids which are arranged at equal angles; the blocking grids are arranged on the core rod, and each blocking grid is located between every two adjacent core rod grids; the blocking device is arranged on the top face of the needle cylinder, and a limiting part is arranged on the side, facing the core rod, of the blocking device and can abut against the blocking grid. According to the fixed-dose injector, the technical problems that the efficiency is low, the accuracy is low and errors are prone to occurring when medical staff determine the liquid pumping amount in a visual mode are solved, and the blocking grid arranged on the core rod and the blocking device arranged on the top face of the needle cylinder are matched with each other; when the core rod drives the rubber plug to be lifted to a set height, the blocking grid abuts against the limiting part, extraction of the fixed-dose liquid medicine is completed, the liquid extraction amount of the injector is accurately controlled, and the purpose of extracting the fixed-dose liquid medicine or accurately dispensing medicine is achieved.

A drug delivery device (100, 200) for delivering a fixed dose, wherein the drug delivery device comprises: a housing assembly, a drug reservoir with a piston and a drive mechanism. The drive mechanism comprises a piston rod (109, 209) for advancing the piston to expel a drug, and a drive tube (180, 280), wherein the drive mechanism is adapted to deliver the predefined fixed dose in response to activation. The drug delivery device further comprises an activation mechanism for activating the drive mechanism, in response to moving the drive tube in an axial direction. The housing assembly comprises a guide structure for guiding the drive tube during activation and delivery of a dose, wherein the guide structure comprises an axial portion (156, 256) providing a sliding surface for guiding the drive tube during activation, and for providing a rotational stop defining an end of dose, and a helical portion (157, 257) providing a sliding surface adapted for guiding the drive tube (180, 280) during dosing. The drive tube (180, 280) comprises a guide structure comprising an axial portion (182, 282) adapted for slidably engaging the axial portion of the housing assembly for activation, and a helical portion (189, 289) for slidably engaging the helical portion of the housing assembly during dosing during dosing.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.

The utility model provides an X-ray adjusting device and X-ray radiotherapy equipment for animal experiments, and the device comprises a fixed plate which is used for being fixed with an X-ray accelerator; the dose adjusting assembly is arranged on one side of the fixing plate, the dose adjusting assembly is telescopic, and the dose and the dose rate are changed through stretching of the dose adjusting assembly. The dose and the dose rate of the X-rays can be changed by adjusting the length of the dose adjusting assembly.

Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflorithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.

The present disclosure provides for fixed-dose combination formulations comprising flavoxate or a pharmaceutically acceptable salt thereof and at least one β3-adrenergic receptor agonist, along with methods of making and using the same to treat symptoms associated with prostate, bladder, urinary tract, and pelvic conditions.

A pharmaceutical composition in a fixed-dose combination is described, comprising: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, and a method for treating or preventing atrial fibrillation or related symptoms in a subject by administering such pharmaceutical composition to a subject in need, and a method for preparing such a fixed-dose combination product.

The present invention relates to a stable, fixed-dose combination formulation comprising sitagliptin or pharmaceutically acceptable salts or derivatives thereof in combination with metformin hydrochloride and one or more pharmaceutically acceptable excipient manufactured by wet granulation method in monolayer dosage form.

The application provides an intelligent postoperative analgesia method and device based on voice recognition control, and relates to the technical field of postoperative analgesia. The method comprises the following steps: initializing the analgesia infusion level of an analgesia pump as an intermediate level, wherein the analgesia pump is provided with multiple levels, and the levels are arranged in ascending order according to the analgesia infusion dose; the analgesia pump is activated by voice in response to the occurrence of discomfort symptoms of a patient, and the analgesia pump is controlled to inquire whether the patient has insufficient analgesia or excessive analgesia; if the patient feeds back insufficient analgesia, the analgesia pump is controlled to execute single-dose administration or to increase the analgesia infusion level; and if the patient feeds back excessive analgesia, the analgesia pump is controlled to suspend drug infusion or to reduce the analgesia infusion level. Through voice control and dynamic dose adjustment technology, convenient operation and individualized analgesia management are realized, the problems of insufficient analgesia or excessive analgesia caused by fixed dose setting in a traditional analgesia pump are avoided, the frequent intervention of medical staff is reduced, and the safety and effect of postoperative analgesia are improved.

The invention discloses an internal rotation type quantitative injection pen, relates to the technical field of medical injection instruments, and aims at solving the problems that a knob of an existing injection pen is prone to disengagement, dosage accuracy is insufficient, feedback is fuzzy, and repeated use risks exist. An internal rotation adjusting assembly of the injection pen is assembled in an outer shell, does not have disengagement displacement along a Z axis and does not have axial force in rotation; the double-sounding feedback assembly provides precise auditory feedback in the dose adjustment stage and the injection stage respectively; the memory limiting assembly accumulatively records injection times through a mechanical structure, and the device is locked after preset times are completed; the elastic driving assembly provides stable injection power and is matched with thread transmission to achieve accurate dose control. The operation stability and the dosage accuracy are improved through structural innovation, the repeated use risk is eradicated through a mechanical locking mechanism, the labor-saving design is suitable for various crowds, the precise self-injection device is suitable for precise self-injection of various chronic diseases, and the remarkable clinical application value is achieved.

Features relating to vaporizer devices configured to provide a fixed amount of aerosol for user consumption are provided. In particular, aspects of the current subject matter relate to utilizing data associated with a cartridge to identify an amount of aerosol to be generated by a vaporizer device, and applying to a heating element an amount of energy to achieve the desired amount of aerosol. Dose control settings may be enabled to provide for the vaporizer device to generate a number of doses based on a selected dose size.

The disclosure relates to fixed dose combinations of the integrin inhibitor bexotegrast ((S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-l,8-naphthyridin-2-yl)butyl)amino)-2- (quinazolin-4-ylamino)butanoic acid) with peroxisome proliferator-activated receptor agonists (PPAR agonists), and methods of treating a subject for a liver fibrotic disease, such as primary sclerosing cholangitis or primary biliary cholangitis, by administration of the fixed dose combinations.

The present invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) netupitant, or a salt or hydrate thereof, and (b) palonosetron, or a salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method for preparing a pharmaceutical composition in the form of a tablet, the method comprises: (i) wet granulating a dry mixture comprising netupitant or a salt or hydrate thereof, a filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules; (ii) blending the particles with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compacting the lubricated particles to produce a tablet. The invention further relates to the use of said pharmaceutical composition for the treatment and / or prevention of nausea and / or vomiting, preferably for the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetically induced cancer chemotherapy, such as cis-platinum cancer chemotherapy.

The invention discloses a dose control method for a human body X-ray security inspection device, and the method comprises the steps: obtaining a height value (H) and a weight value (W) of a detected person before scanning, and calculating a weight-height ratio (R) of the detected person; calculating a target dose value Dtarget according to a formula Dtarget = D0 + K * R; the target dose value is compared with preset dose upper and lower limits (Dmax, Dmin) to determine a final emission dose (final dose value Dfinal). Personalized adjustment of the scanning dose is carried out according to the obesity degree (quantified through the weight-height ratio) of the detected person, and unnecessary radiation irradiation on the detected person with a thin and small body shape can be reduced; meanwhile, compared with traditional X-ray scanning with a fixed dose value, an image with a higher signal-to-noise ratio and clearer details can be obtained for an obese detected person, so that a security check person can identify dangerous articles possibly existing in the image, and the accuracy and safety of security check are improved.

Embodiments relate to systems comprising Active Wearable Medical Device (AWMD) with an osmotic chamber containing or configured to receive an osmotic agent, a permeability module for fluid ingress, and a drug chamber holding a drug. A compressible piston, positioned between the chambers, moves longitudinally as a whole during operation. The compressible piston advances toward the drug chamber when a valve opens, enabling drug release through one or more outlets, and retracts when the valve closes, driven by osmotic pressure. A valve module regulates this flow. The system also comprises a fluid chamber containing fluid and a semipermeable membrane coupling it to the AWMD. A channel connected to the drug outlets delivers the drug externally.

The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.

Provided herein are fixed dosage combinations of durlobactam and sulbactam along with their use in treating one or more bacterial infections.

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.

Combination therapy comprising inalipase and a fixed-dose combination (PH FDC SC) of pertuzumab and trastuzumab for subcutaneous injection is provided for the treatment of HER2-positive cancer; and a method for treating PIK3CA-mutated HER2-positive (HER2+) locally advanced or metastatic breast cancer, the method comprising administering a therapeutically effective amount of inalipase and PH FDC SC.

The invention relates to a reuseable injection device (1) for ejecting a plurality of fixed doses of a liquid drug from a replaceable cartridge, wherein a piston rod arrangement (50) is divided into two separate parts, i.e., a washer part (52) and a rod part (51), the two parts being urged away axially from each other by a spring element (53). When a new cartridge assembly (20) is attached to housing structure (10), the washer part (52) of the piston rod arrangement (50) is moved proximally against the force of the spring element (53) by engagement with the plunger (42) inside the cartridge (40) thereby accumulating force in spring element (53). Upon mounting of an injection needle onto the cartridge assembly (20) the accumulated force urges the washer part (52) in the distal direction back to its initial position thus performing an automatic priming of the injection device (1).

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and / or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

1. Name of the product of this design: Automatic injection pen (two-step). 2. Purpose of the product with this design: The product with this design is used for self-administration by patients, automatic subcutaneous injection of liquid medicine or biological agents, and injection of fixed doses of liquid medicine or biological agents. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.